Mechanism of Action

EGRIFTA SV®: A unique mechanism of action that helps break down excess visceral abdominal fat in PWHIV

GH deficiency has been observed in PWHIV.

GH plays an important role in the formation and function of fat cells as well as the overall regulation of fat metabolism.1

EGRIFTA SV® is an analog of GHRH that stimulates the body to secrete its own GH in a pulsatile manner, resulting in both anabolic and lipolytic effects.2

EGRIFTA SV® stimulates endogenous GH secretion without changing the pulse frequency; mimicking the body's natural hormone release.3

The solution to excess visceral abdominal fat may not be diet and exercise alone.

GH = growth hormone; GHRH = growth hormone releasing hormone; IGF = insulin‑like growth factor; PWHIV = people with HIV.


  1. Stanley TL, Grinspoon SK. Effects of growth hormone‑releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res. 2015;25(2):59-65.
  2. EGRIFTA SV® (tesamorelin for injection) Prescribing Information. Theratechnologies Inc. October 2019.
  3. Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone‑releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158.

IMPORTANT SAFETY INFORMATION (Please see below for full limitations of use and additional important safety information)


EGRIFTA SV® is indicated for the reduction of excess abdominal fat in HIV‑infected adult patients with lipodystrophy.

Limitations of Use:

  • The impact and safety of EGRIFTA SV® on cardiovascular health have not been studied.
  • EGRIFTA SV® is not indicated for weight loss management.
  • It is not known whether taking EGRIFTA SV® helps improve compliance with anti‑retroviral medications.


Do not use EGRIFTA SV® if patient:

  • Has a pituitary gland tumor, has had pituitary gland surgery, has other problems related to their pituitary gland, or has had radiation treatment to their head or a head injury.
  • Has active cancer.
  • Is allergic to tesamorelin or any of the ingredients in EGRIFTA SV®.
  • Is pregnant or planning to become pregnant.

Warnings and Precautions

Drug Interactions

Use in Specific Populations

Adverse Reactions

The most commonly reported adverse reactions include injection site reactions, arthralgia, pain in extremity, myalgia, and peripheral edema.

To report suspected adverse reactions, contact THERA patient support® at 1‑833‑23THERA (1‑833‑238-4372) or FDA at 1‑800‑FDA-1088 or

Please see full Prescribing Information for EGRIFTA SV®.